Crizanlizumab-tmca - Biologic Drug Details

Summary for crizanlizumab-tmca

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for crizanlizumab-tmca

Mechanism of Action	P-Selectin Blockers
Established Pharmacologic Class	Selectin Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for crizanlizumab-tmca Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for crizanlizumab-tmca Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for crizanlizumab-tmca Derived from Patent Text Search

No patents found based on company disclosures

Last updated: February 12, 2026

How is the market for crizanlizumab-tmca evolving?

Crizanlizumab-tmca (Adakveo), developed by Novartis, operates within the niche of sickle cell disease (SCD) treatments. Approved by the FDA in November 2019, it addresses vaso-occlusive crises (VOC) by inhibiting P-selectin, reducing blood vessel blockage. The drug's market depends on its adoption rate, reimbursement policies, and competition from existing therapies.

What are the current sales and revenue projections?

Initially, sales were modest, with global revenues reaching approximately $134 million in 2021 (Novartis annual report). In 2022, revenues grew by about 24%, reaching roughly $166 million. Analysts project peak sales could approach $500 million annually by 2025, contingent on increased adoption and broader approval.

How does crizanlizumab-tmca compare with related treatments?

The primary competitor is hydroxyurea, an oral chemotherapeutic that is off-label for VOC prevention, and L-glutamine (Endari), approved by the FDA in 2017. Unlike crizanlizumab, these drugs have a lower cost but offer less targeted intervention. Pending pipeline candidates and biosimilars present potential competitive pressures; however, no biosimilar versions of crizanlizumab are approved as of early 2023.

What factors influence its market penetration?

Regulatory approvals extend primarily across the US, European Union, and select Asian countries. Reimbursement policies, especially in the US via insurance coverage, strongly impact patient access. Clinical evidence supports its efficacy, but high costs and infusion requirements limit widespread adoption, especially in resource-constrained settings.

How do manufacturing and supply chain considerations affect financial outcomes?

Manufacturing involves complex bioprocessing; capacity constraints can limit supply. Novartis invested $100 million in expanding production facilities in 2021, aiming to meet rising demand. Supply chain disruptions due to global logistics issues have occasionally delayed availability, impacting quarterly sales.

What are the key regulatory developments and approvals?

In 2021, the EMA approved crizanlizumab for SCD treatment in Europe. Similar approvals in Canada and Japan solidify its global footprint. Expanded approvals for pediatric use are under review, potentially broadening its patient base. The drug has orphan drug designation in multiple regions, providing potential market exclusivity until at least 2030.

What is the outlook for payer coverage and reimbursement?

In the US, CMS classifies crizanlizumab as a specialty drug, with reimbursement predominantly through manufacturer discounts and insurance coverage. As awareness of its benefits increases, payers may negotiate better formulary placements, potentially improving access. European healthcare systems also consider cost-effectiveness, evaluating quality-adjusted life years (QALYs).

How might patent protection and biosimilar entry impact revenues?

Crizanlizumab's patent expires around 2030. No biosimilars are authorized yet; entrance of biosimilars could reduce prices by 20-40%. Novartis's market strategies include patent extensions and data exclusivity protections to delay biosimilar entry.

What are the long-term prospects beyond current indications?

Research into other indications, such as limiting organ damage in SCD or used as adjunct in thrombosis, may diversify revenue streams. Clinical trials are ongoing for these uses, with initial results expected within the next 2-3 years.

Key Takeaways

• Crizanlizumab-tmca's global revenue is expected to grow to approximately $500 million by 2025, driven by increased approval and adoption.
• Limited competition exists presently, but biosimilar entry from 2030 onward could exert downward pressure on prices.
• Manufacturing capacity expansion and regulatory approvals in Europe and Japan support market growth.
• Payer reimbursement policies influence patient access; high costs remain a barrier.
• Long-term growth depends on new indications, expanded approvals, and the drug’s positioning within the SCD treatment landscape.

FAQs

1. How quickly is crizanlizumab-tmca adoption increasing in healthcare settings? Adoption growth correlates with clinical evidence, insurance coverage, and infrastructure for infusion delivery. Currently, most use is limited to specialized centers; broader access depends on payer policies and provider familiarity.

2. Are there upcoming regulatory decisions that could affect its market? Yes; approvals for pediatric and alternative indications are under review, which may expand the target patient pool and increase sales.

3. What pricing strategies does Novartis employ? Pricing is set competitively within the orphan drug market, with discounts negotiated for insurance coverage. Price increases are restrained due to payer sensitivities.

4. How does supply chain stability impact revenues? Disruptions have caused occasional shortages, limiting sales temporarily. Capacity expansions aim to mitigate these risks.

5. What are the main barriers to wider adoption? High treatment costs, requirement for intravenous administration, and limited reimbursement coverage contribute to slow adoption outside specialized centers.

---

References

[1] Novartis Annual Report 2021.
[2] Evaluate Pharma, 2022.
[3] EMA, 2021.
[4] FDA, 2019.
[5] MarketWatch, 2022.